<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306263</url>
  </required_header>
  <id_info>
    <org_study_id>EARLY-TOLERA</org_study_id>
    <nct_id>NCT04306263</nct_id>
  </id_info>
  <brief_title>Effect of a New Infant Formula With Specific Ingredients</brief_title>
  <acronym>EARLY-TOLERA</acronym>
  <official_title>Evaluation of the Effect of a New Infant Formula With Specific Ingredients on the Development of the Immune System and the Gastrointestinal Health of the Infant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Ordesa</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Ordesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the addition of certain bioactive ingredients to&#xD;
      a new infant formula (HMOs, osteopontin and probiotics) can have a favorable impact on the&#xD;
      development of the infant's immune system in the first months of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays, almost all commercial infant formulas resemble the &quot;gold standard&quot; of breast milk&#xD;
      in terms of composition of essential nutrients, but it is still a challenge to identify and&#xD;
      incorporate certain bioactive components capable of replicating those stimuli typical of&#xD;
      breast milk that can program growth, infant development and maturation of the immune system.&#xD;
&#xD;
      The purpose of this study is to test whether the addition of certain bioactive ingredients to&#xD;
      a new infant formula (HMOs, osteopontin and probiotics) can have a favorable impact on the&#xD;
      development of the infant's immune system in the first months of life.&#xD;
&#xD;
      In addition, considering that the quality of feeding at these early ages will program (Early&#xD;
      programming) the health and physiology of the child and the future adult, the study wants to&#xD;
      obtain evidence of the effects of this new infant formula on the immune system and the&#xD;
      development of the child compared to breast milk during the first year of life, hoping that&#xD;
      it promotes proper growth, adequate cognitive development and maturation of the immune system&#xD;
      as similar as possible to children fed to the mother's breast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Register of infections</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <description>Register of infant infections through patient diaries completed by parents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Register of fever episodes</measure>
    <time_frame>From baseline to 12 months.</time_frame>
    <description>Presence and duration of the fever and treatments, through diaries completed by parents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Register of diarrhea episodes</measure>
    <time_frame>From baseline to 12 months.</time_frame>
    <description>Presence and duration of diarrhea, registered in patients dairies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response evaluation</measure>
    <time_frame>At 3, 6 and 12 months of age</time_frame>
    <description>registration of Immunoglobulin secreted in saliva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographic data</measure>
    <time_frame>From baseline to 12 months.</time_frame>
    <description>age of the parents, educational level of the parents, habits and lifestyles of the parents, residence and social environment of the infant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetric background</measure>
    <time_frame>Baseline</time_frame>
    <description>Relevant obstetric background</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of the infant microbiota</measure>
    <time_frame>At 3, 6 and 12 months.</time_frame>
    <description>Stool bacteria count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of normal growth of the infant</measure>
    <time_frame>From baseline to 12 months.</time_frame>
    <description>Evolution of Weight (g), Size (cm) to calculate the Body Mass Index.weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant neurodevelopment</measure>
    <time_frame>At 12 months</time_frame>
    <description>Analysis of eye movements. Eye tracking technologies is using to assess early cognitive development to evaluate attention domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant neurodevelopment 2</measure>
    <time_frame>At 2, 3, 4, 6, 9 and 12 months of age.</time_frame>
    <description>ASQ-3 (Ages &amp; Stages Questionnaires®) ASQ-3 is a set of questionnaires about children's development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant neurodevelopment 3</measure>
    <time_frame>At 2, 3 and 4 months of life.</time_frame>
    <description>General Movements test (GM´s) GM's is using for the neurological assessment during the first months of life and measures a series of gross movements of variable amplitude and speed involving all body parts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant neurodevelopment 4</measure>
    <time_frame>6 and 12 months of age</time_frame>
    <description>Bayley´s Scales of Infant Development III (Spanish version BSID III) is using to evaluate psychomotor and mental development .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant neurodevelopment 5</measure>
    <time_frame>12 months of age</time_frame>
    <description>MacArthur Communicative Development Inventory (CDI) . This test assesses the normal process of early language acquisition by various manifestations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Infant Growth</condition>
  <arm_group>
    <arm_group_label>Enriched infant formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant formula enriched with dairy ingredients: osteopontin, prebiotics (Human milk oligosaccharide, Glucooligosaccharides) and probiotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants receiving a standard infant formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breastfeeding arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants exclusively or predominantly breastfed (&gt;75%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Enriched infant formula</intervention_name>
    <description>Infant formula enriched with dairy ingredients: osteopontin, prebiotics and probiotics</description>
    <arm_group_label>Enriched infant formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard formula</intervention_name>
    <description>Infants receiving a standard infant formula.</description>
    <arm_group_label>Standard formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Breastfeeding arm</intervention_name>
    <description>Infants exclusively or predominantly breastfed (&gt;75%).</description>
    <arm_group_label>Breastfeeding arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion age from 0 to 2.5 months of age.&#xD;
&#xD;
          -  Gestational age &gt;37 weeks and &lt;41 weeks inclusive.&#xD;
&#xD;
          -  Appropriate birth weight appropriate for your gestational age (between 10-90&#xD;
             percentiles).&#xD;
&#xD;
          -  APGAR score normal birth to 1' and 5' of 7 - 10.&#xD;
&#xD;
          -  Umbilical pH ≥ 7.10.&#xD;
&#xD;
          -  Availability to continue throughout the study period.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Additional Inclusion Criteria for groups 1 and 2:&#xD;
&#xD;
          -  Infants who, at the time of recruitment, have already passed the diet with a majority&#xD;
             or exclusive formula for medical reasons, by decision of the parents or any other&#xD;
             reason agreed with the pediatrician.&#xD;
&#xD;
        Additional Inclusion Criteria for group 3 (breastfeed infants):&#xD;
&#xD;
          -  Infants who have been breastfed until the second month with exclusive or majority&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Infants who are expected to be exclusively or predominantly breastfed up to 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous participation in other clinical trials.&#xD;
&#xD;
          -  Infants suffering from gastrointestinal disorders (allergy and/or intolerance to cow's&#xD;
             milk protein or lactose).&#xD;
&#xD;
          -  Mother's pathology history and during gestation: neurological diseases, metabolic&#xD;
             disorders, type 1 diabetes mellitus, chronic disease (hypothyroidism), maternal&#xD;
             malnutrition, TORCH syndrome.&#xD;
&#xD;
          -  Treatment of the mother's anxiolytics or antidepressants. Other treatments with drugs&#xD;
             potentially harmful to neurodevelopment.&#xD;
&#xD;
          -  Inability of the parents to follow up the study (medical decision).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Campoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EURISTIKOS Excellence Centre for Paediatric Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roser De Castellar, MD</last_name>
    <phone>902 10 52 43</phone>
    <email>roser.decastellar@ordesa.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Campoy, MD</last_name>
    <phone>+34629308695</phone>
    <email>ccampoy@ugr.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cristina Campoy</name>
      <address>
        <city>Granada</city>
        <state>Andalucia</state>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Campoy, MD</last_name>
      <phone>+34629308695</phone>
      <email>ccampoy@ugr.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

